[Skip to Content]
[Skip to Content Landing]
Article
February 1989

Intravenous Immunoglobulin Therapy in Human Immunodeficiency Virus—Associated Thrombocytopenia

Author Affiliations

Providence, RI

Arch Intern Med. 1989;149(2):467. doi:10.1001/archinte.1989.00390020151036
Abstract

To the Editor.—Pollak et al,1 in their report on intravenous immunoglobulin therapy for human immunodeficiency virus-associated thrombocytopenia, state that the necessity to use a continuous intravenous infusion for immunoglobulin therapy requires hospitalization. However, I have recently treated three patients with human immunodeficiency virus—associated thrombocytopenia at home with intravenously administered immunoglobulin. The patients all received five daily doses of 0.4 g/kg administered over three to four hours. The first dose in each case was administered by a nurse from a home care agency in my office. The subsequent doses for four days were administered in the patients' homes. No complications related to either the product or the infusion were encountered. Indeed, intravenously administered immunoglobulin is extremely expensive; the additional cost of hospitalization is probably avoidable.

×